Rallybio Corp

For the period ended Jun 30, 2024. Filed Aug 8, 2024.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2024 · Filed Aug 8, 2024

RLYB$15.76+0.6%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Unaudited Condensed Consolidated Statements of Operations and Comprehensive Loss

Condensed Consolidated Statements of Operations and Comprehensive Loss

	FOR THE THREE MONTHS ENDED JUNE 30,		FOR THE SIX MONTHS ENDED JUNE 30,
(in thousands, except share and per share amounts)	2024	2023	2024	2023
Revenue:
Collaboration and license revenue	$299	$—	$299	$—
Total revenue	299	—	299	—
Operating expenses:
Research and development	12,946	13,130	25,882	24,332
General and administrative	4,388	6,953	11,239	14,125
Total operating expenses	17,334	20,083	37,121	38,457
Loss from operations	(17,035)	(20,083)	(36,822)	(38,457)
Other income:
Interest income	1,143	1,608	2,419	3,154
Other income	143	62	310	135
Total other income, net	1,286	1,670	2,729	3,289
Loss before equity in losses of joint venture	(15,749)	(18,413)	(34,093)	(35,168)
Loss on investment in joint venture	487	217	1,172	780
Net loss	$(16,236)	$(18,630)	$(35,265)	$(35,948)
Net loss per common share, basic and diluted	$(0.37)	$(0.46)	$(0.83)	$(0.89)
Weighted-average common shares outstanding, basic and diluted	44,128,059	40,363,902	42,450,837	40,306,715
Other comprehensive loss:
Net unrealized loss on marketable securities	—	(211)	(86)	(58)
Other comprehensive loss	—	(211)	(86)	(58)
Comprehensive loss	$(16,236)	$(18,841)	$(35,351)	$(36,006)

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.